JAC Advance Access published online on October 16, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn412
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance
1 Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK 2 Camden Primary Care Trust, London, UK 3 Division of Infection and Immunity, University College, London, UK
Received 22 May 2008; returned 4 August 2008; revised 11 August 2008; accepted 6 September 2008
* Corresponding author. Tel: +44-20-8327-6470; Fax: +44-20-8200-1569; E-mail: andrew.buckton{at}hpa.org.uk
Objectives: We present the evaluation of a methodology for the genotypic assessment of human immunodeficiency virus type-1 (HIV-1) drug resistance, optimized for use with dried blood spots (DBS).
Methods: The ability to generate HIV-1 protease (PR) and reverse transcriptase (RT) contiguous amplicons and nucleotide sequences from DBS was evaluated. Different collection matrices and extraction methodologies were compared. The relative subtype sensitivity of the amplification strategy was assessed using a comprehensive panel of plasmids representing A–H subtypes. A panel of DBS and plasma specimens was subjected to HIV genotyping. Sequences generated from each sample type were compared.
Results: Extensive replicate testing revealed most sensitivity with the use of 903 filter paper and silica/guanidine extraction, which had an estimated 95% inclusivity endpoint of 1542 proviral copies/mL, as compared with 21 573 proviral copies/mL for the FTA system. All HIV-1 group M subtypes analysed—with the exception of subtypes A2, AE, AG, F and H—had a relative sensitivity of 
10 plasmid copies/PCR reaction. The PCR was multiplexed to include amplification of a human housekeeping gene to monitor the integrity of the human genomic DNA. Using a panel of clinical samples, we demonstrated the ability to amplify and sequence from 83% (n = 10) in the PR region and 100% (n = 12) in the RT region, of samples with detectable viral load. All specimens with an HIV-1 RNA load 
1000 copies/mL were successfully amplified and sequenced. Twelve specimens had pol genotyping from both plasma and DBS samples. Sequence analysis and drug resistance interpretation revealed that 10 (83%) provided concordant drug resistance interpretation.
Conclusions: Our results demonstrate that the technique is appropriate for surveillance of drug resistance in untreated individuals and those with virological failure on therapy.
Key Words: HIV-1 , filter paper , antiretrovirals , scale-up
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Johannessen, M. Troseid, and A. Calmy Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings J. Antimicrob. Chemother., December 1, 2009; 64(6): 1126 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Cane New developments in HIV drug resistance J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i37 - i40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Garcia-Lerma, A. McNulty, C. Jennings, D. Huang, W. Heneine, and J. W. Bremer Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37{degrees}C and high humidity J. Antimicrob. Chemother., July 1, 2009; 64(1): 33 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Buckton, D. P. Prabhu, P. A. Cane, and D. Pillay No evidence for cross-contamination of dried blood spots excised using an office hole-punch for HIV-1 drug resistance genotyping J. Antimicrob. Chemother., March 1, 2009; 63(3): 615 - 616. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kudrin Challenges in the Clinical Development Requirements for the Marketing Authorization of New Medicines in Southeast Asia J. Clin. Pharmacol., March 1, 2009; 49(3): 268 - 280. [Abstract] [Full Text] [PDF]
|
|